Optimized Posaconazole Treatment Systems and Methods

Publication ID: 24-11857548_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Optimized Posaconazole Treatment Systems and Methods,” Published Technical Disclosure No. 24-11857548_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857548_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,548.

Summary of the Inventive Concept

The present inventive concept relates to systems and methods for optimizing posaconazole treatment in immunocompromised patients, addressing limitations of existing treatment methods and improving patient outcomes.

Background and Problem Solved

The original patent, 'Methods of treatment', discloses methods for treating various diseases with posaconazole. However, these methods have limitations, such as inadequate patient response monitoring, suboptimal dosing, and increased risk of invasive Aspergillus and Candida infections. The present inventive concept addresses these limitations by providing systems and methods for personalized posaconazole treatment planning, real-time patient response monitoring, and dosing adjustments based on patient-specific factors, thereby improving treatment efficacy and reducing the risk of adverse effects.

Detailed Description of the Inventive Concept

The inventive concept comprises a monitoring module that tracks patient response to posaconazole, a dosing adjustment module that adjusts posaconazole dosage based on patient response, and a computer-implemented method for personalized posaconazole treatment planning. The system takes into account patient-specific factors, such as CYP3A4 substrate drug regimen and medical history, to generate a tailored treatment plan. Additionally, the inventive concept includes methods for reducing the risk of invasive Aspergillus and Candida infections by administering posaconazole in combination with a CYP3A4 inhibitor and an immune system stimulant.

Novelty and Inventive Step

The present inventive concept introduces novel systems and methods for optimizing posaconazole treatment, including personalized treatment planning, real-time patient response monitoring, and dosing adjustments based on patient-specific factors. These features are not disclosed in the original patent and provide a significant improvement over existing treatment methods.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include variations in the monitoring module, such as using different biomarkers or sensors to track patient response. Additionally, the dosing adjustment module may be implemented using different algorithms or machine learning models. The computer-implemented method for personalized posaconazole treatment planning may be adapted for use in different clinical settings or patient populations.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of oncology, hematology, and infectious diseases. The optimized posaconazole treatment systems and methods may be marketed as a premium service or product, offering improved patient outcomes and reduced healthcare costs.

Field of Art

Pharmaceutical treatment methods, specifically immunocompromised patient care, antifungal therapeutics, and personalized medicine involving drug metabolism and treatment optimization

Person of Ordinary Skill (PHOSITA) Profile

A clinical pharmacologist or medical researcher with expertise in antifungal treatments, drug metabolism, personalized medicine techniques, and experience with immunocompromised patient care protocols

Obviousness Rationale

A PHOSITA would recognize that the PTD's personalized treatment approach represents a predictable extension of existing posaconazole treatment methods, leveraging known pharmacogenomic principles and standard clinical monitoring techniques to optimize drug administration for immunocompromised patients.

Obvious Combinations & Variations

Source Patent Element
Treatment method for immunocompromised patients using posaconazole
PTD Variation
Adding a monitoring module to track patient response and dynamically adjust dosage
Obviousness Reasoning
Personalized dosing is a known technique in clinical pharmacology, and real-time patient monitoring represents a predictable improvement in treatment optimization
Source Patent Element
Posaconazole administration for preventing invasive fungal infections
PTD Variation
Combining posaconazole with a CYP3A4 inhibitor to enhance drug effectiveness
Obviousness Reasoning
Drug interaction strategies to improve metabolic processing are well-established in pharmaceutical research, and combining medications to enhance therapeutic outcomes is a standard clinical approach
Source Patent Element
Treatment of immunocompromised patients with hematologic conditions
PTD Variation
Implementing a computer-implemented method for personalized treatment planning
Obviousness Reasoning
Computational approaches to treatment planning are a predictable technological advancement in personalized medicine, representing an obvious application of existing clinical knowledge with computational tools
Source Patent Element
Posaconazole use in managing patient infections
PTD Variation
Adding an immune system stimulant to enhance treatment efficacy
Obviousness Reasoning
Combination therapies that simultaneously target multiple aspects of patient immune response are a known strategy in treating immunocompromised patients
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857548, a person of ordinary skill in the art would find the variations disclosed in this publication to be obvious extensions of existing posaconazole treatment methods. The proposed personalized treatment system represents a predictable combination of known clinical techniques, computational methods, and pharmacological principles, thereby rendering potential claims covering similar approaches obvious and unpatentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,548
TitleMethods of treatment
Assignee(s)BOW RIVER LLC